Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesA phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
Lung Cancer, 10/30/09
Kaira K et al. – Amrubicin is an active and well–tolerated regimen in patients with previously treated lung cancer. Amrubicin 35mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor